Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Solid Tumor Cancer 1Metastatic Gastric Adenocarcinoma 1HER2 IHC3+ Advanced Colorectal Cancer 1Colonic Neoplasms 1

Interventions

Oxaliplatin 14Leucovorin 12Fluorouracil 12Cetuximab 10Bevacizumab 9pembrolizumab 7Specimen Handling 7Nivolumab 6Magnetic Resonance Spectroscopy 6Irinotecan 5encorafenib 4Pemetrexed 4Gemcitabine 4Cisplatin 4Capecitabine 4fludarabine 3cemiplimab 3Laparoscopy 3Folfox protocol 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3trifluridine tipiracil drug combination 2pertuzumab 2durvalumab 2dehydroftorafur 2aldesleukin 2X-Rays 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × tipiracil × 90 days × Clear all
NCT04920032 2026-05-11

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

University of California, Irvine

Phase 1 Recruiting
22 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡